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HSP70 Peptide Binding Mutants Separate
Antigen Delivery from Dendritic Cell Stimulation
is of interest both as a potential mechanism for the
crosspresentation of antigen and a tool to stimulate an
effective and protective CD8 CTL response. A role for
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HSPs in crosspresentation has been proposed (Singh-1Division of Immunology
Jasuja et al., 2000), and gp96 bound peptides can beDepartment of Medicine
loaded onto MHC class I molecules in an endosomalCambridge Institute for Medical Research
compartment (Berwin et al., 2002), though a physiologi-Addenbrooke’s Hospital
cal role for HSPs in crosspresentation has not been dem-Hills Road
onstrated.Cambridge CB2 2XY
HSP70 contains an N-terminal ATPase subunit (44United Kingdom
kDa) and a C-terminal peptide binding domain (27 kDa).2 Lionex Diagnostics & Therapeutics GmbH
Structural analysis of bacterial HSP70 (DnaK) shows aMascheroder Weg 1b
single hydrophobic binding channel (Zhu et al., 1996),D-38124 Braunschweig
and polypeptide access to this site is controlled by nu-Germany
cleotide. Binding of ATP to the nucleotide binding do-
main induces a conformational change that opens a
helical lid and allows access to the substrate bindingSummary
cavity. Following hydrolysis of ATP to ADP, the helical
lid is closed, preventing access to the cavity and re-Microbial heat shock proteins (HSPs) have been impli-
sulting in slow “on” and “off” rates for bound substrate.cated in the induction of both the innate and adaptive
However, even in the absence of the ATPase domain,arms of the immune response. We now show that
truncated HSP70 proteins are able to bind peptides (Zhuhuman dendritic cells (DC) pulsed with peptide-loaded
et al., 1996).mycobacterial HSP70 complexes generate potent an-
While the specificity of HSPs can be attributed totigen-specific cytotoxic lymphocyte (CTL) responses,
peptide occupancy of the substrate binding domain,which are dependent on an HSP70-stimulated calcium
the effectiveness of HSPs as adjuvants relies on theirsignaling cascade. From the calculated peptide bind-
proinflammatory activity. Different HSPs can activateing affinity of mycobacterial HSP70 (KD  14 M) we
innate immune cells both in vivo and in vitro; for example,show that 120 pM HSP70 bound peptide is sufficient
they have been shown to stimulate DC to secrete pro-to generate a peptide-specific CTL response that is
inflammatory cytokines and chemokines (Cho et al.,up to four orders of magnitude more efficient than
2000). How this activation occurs is less well under-peptide alone. The minimal 136 amino acid, mycobac-
stood. Specific HSP binding to the cell surface of bothterial HSP70 peptide binding domain can generate CTL
murine and human DC and monocytes has been demon-responses, and a single amino acid mutant HSP70
strated (Arnold-Schild et al., 1999; Castellino et al. 2000;designed to prevent peptide binding but retain stimula-
Lipsker et al., 2002) and receptors described, includingtory capacity has allowed us to separate antigen deliv-
CD91, 14, 40, TLR4, and Lox-1 (Asea et al., 2000; Basuery from DC immunostimulation.
et al., 2001; Becker et al., 2002; Delneste et al., 2002;
Ohashi et al., 2000; Vabulas et al., 2001; Wang et al.,Introduction
2001). Which receptors are responsible for specific up-
take and/or proinflammatory signaling remains to be de-
The conserved heat shock protein (HSP) family is widely
termined.
distributed in microorganisms and mammalian cells.
The difficulty of generating CTL responses to exoge-
HSPs have several important biological properties in- nous proteins remains a major stumbling block to the
cluding participation in the assembly and disassembly development of effective vaccines. The potential of
of proteins and interaction with shorter polypeptides HSPs to chaperone such exogenous peptides to MHC
(Gething and Sambrook, 1992). This latter function is of class I molecules and thus generate antigen-speci-
particular interest to immunologists, as the induction of fic CD8 CTL responses, in the absence of further
protective tumor immunity and the generation of tumor- adjuvants, makes them attractive vaccine candidates.
specific CTL have been ascribed to HSPs and their Indeed, clinical trials using tumor-derived HSPs and
bound peptides (reviewed in Srivastava, 2002) The CTL HSP fusion proteins as immunogens have been
specificity for the tumor cells from which the HSPs were prompted by the ability of HSPs to generate in vivo and
derived is explained by the association of HSPs with in vitro peptide-specific CTL responses in mice (Belli et
cellular peptides, and the subsequent generation of a al., 2002). However, there have been few studies on the
peptide-specific immune response. The original obser- mechanism and effectiveness of HSPs in eliciting antigen-
vation of immunity to tumor-derived antigens has been specific responses in a human system (Noessner et
expanded to viral antigens (Ciupitu et al., 1998). al., 2002).
This ability of HSPs to induce peptide-specific CTL If HSPs are to be of therapeutic use, it is critical to
understand how they bind peptides, their peptide bind-
ing affinity, and the minimal HSP unit required to bind*Correspondence: pjl30@cam.ac.uk
3 These authors contributed equally to this work. peptide and thus generate CTL. The aim of this paper
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is to define the key features of HSP70 required for the at concentrations of 250 nM or above (Figure 1B), show-
ing a clear processing requirement for the NRL-M1 17-efficient generation of CTL by human DC. Since the
structural basis for peptide binding is best understood mer peptide. Following dialysis of both the NRL-M1 pep-
tide and M1 peptide, no sensitization for CTL lysis wasfor HSP70, we investigated the ability of mycobacterial
HSP70-pulsed human DC to generate peptide-specific seen, demonstrating successful removal of free peptide
(Figure 1B).CTL. We show that human DC pulsed with mycobacterial
HSP70-peptide complexes efficiently generate peptide- Using the mycobacterial HSP70 bound peptides, cells
from 12/12 HLA-A*0201 healthy donors generated M1specific CTL and are more potent than either peptide
alone or other DC activators. Truncated HSP70 con- peptide-specific CTL with specific lysis ranging between
19% and 55% at an E:T ratio of 10:1. The maximal re-taining the minimal 136 amino acid peptide binding do-
main is sufficient to elicit a CTL response. We show that sponse was seen with mycobacterial HSP70 complexed
with the 17-mer extended peptide (NRL-M1), which byHSP70 mutant proteins with a reduced peptide binding
affinity induce DC to release chemokines and cytokines, tetramer staining showed 35% of cells to be HLA-
A*0201/M1 positive (Figure 1C, i). Mycobacterial HSP70-but are unable to generate an antigen-specific CTL re-
sponse. Thus, we have separated the innate immuno- M1 peptide complexes also generated an efficient CTL
response (26.8% tetramer-positive) (Figure 1C, ii). Therestimulatory properties of HSP70 from its ability to elicit
an antigen-specific CTL response. We thus provide evi- was a clear requirement for DC as CD8 T lymphocytes
alone did not respond to HSP70-peptide stimulationdence of the effectiveness of mycobacterial HSP70 in
generating human CTL responses, which has implica- (Figure 1C, iii and iv). In the absence of HSP70, pulsing
DC with free undialyzed M1 or extended M1 peptidestions for our understanding of both the immune re-
sponse and the rational design of vaccines. was unable to elicit significant CTL responses, even at
peptide concentrations as high as 250 nM (Figure 1C, v
and vi). Furthermore, the efficient generation of peptide-Results
specific CTL by the HSP70-peptide complexes was not
simply due to activation of the DC by the HSP70. LPS,Human DC Pulsed with Mycobacterial HSP70 Bound
a potent DC activator, together with either the M1 orPeptides Generate Efficient Antigen-Specific
extended M1 peptide (250 nM) induced only a minimalCTL Responses
CTL response (Figure 1C, vii and viii).To determine whether human DC pulsed with mycobac-
A remarkably small number of HSP70-peptide-pulsedterial HSP70 bound peptide generate an antigen-spe-
DC are required to generate a peptide-specific CTL re-cific human CTL response, we modified a protocol de-
sponse. Even at a CD8:DC ratio as high as 5000:1 (abso-vised by Bhardwaj and colleagues (Bhardwaj et al., 1994)
lute number of 50 DC per well) (Figure 1D), we were(Figure 1A). This assay measures the ability of antigen-
able to generate a CTL response significantly abovepulsed DC to generate an effector CTL population from
background. The maximal level of killing was observedfreshly isolated CD8 T lymphocytes and represents a
at a CD8:DC ratio of 25:1 and was used in subsequentstringent test of antigen presentation. In brief, day 7
experiments. The generation of peptide-specific CTLimmature monocyte-derived DC are pulsed for 2–4 hr
by HSP70 is not unique to HLA-A*0201- or influenzawith dialyzed mycobacterial HSP70-peptide complexes.
A-derived epitopes. Human cytomegalovirus (HCMV)-Following removal of the unbound HSP70-peptide com-
specific CTL could also be generated using the HLA-plexes, the pulsed DC are cocultured for a further 7 days
A*0201-restricted, HCMV-derived pp65 peptide (Figurewith purified autologous CD8 T lymphocytes. Peptide-
1E), and HLA-B8- (Figure 2A) and -B27-restricted re-specific CTL are then assayed in a standard cytotoxicity
sponses have also been generated.assay or by flow cytometry using MHC class I tetramers.
To improve peptide binding to HSPs, we designed fusion
peptides (17–23-mers) which contain an N-terminal HSP70 Peptide Competition for HSP70 Binding Affects
the Generation of the Effector CTL Populationbinding motif (HWDFAWPW [Moroi et al., 2000] or
NRLLLTG [Zhu et al., 1996]) connected via a linker region To determine whether specificity of peptide binding for
HSP70 affects CTL generation, we set up an assay to(S or SG, respectively) to influenza A-derivedHLA-A*0201
(GILGFVFTL) or HLA-B8/B27 (ELRSRWAIRTR)-restricted show competition for HSP-peptide binding between the
HLA-A*0201-restricted, HWD-M1 peptide and the HLA-CTL epitopes. In the murine system, fusion peptides with
the BiP-derived HWDFAWPW sequence at the N terminus B8-restricted, HWD-NP peptide. These fusion peptides
share the same HSP70 binding motif (HWD-) but encodeof the antigenic peptide were shown to require processing
via a proteasome-independent pathway (Castellino et al. different influenza A epitopes. The HLA-B8-restricted
peptide was used at a fixed predialysis concentration2000).
To ensure that our assay measured the effect of the of 150 nM while the HLA-A*0201-restricted HWD-M1
peptide was titrated from 0–10 M (predialysis concen-HSP70-complexed peptide, and not free peptide, it was
necessary to remove unbound peptide from the HSP70- tration). The donor was HLA-A*0201, B8 positive, and
CTL killing was assayed on peptide-sensitized C1R.A2peptide mixture. This was achieved by overnight mi-
crodialysis as determined in a biological peptide sensiti- or C1R.B8 cell lines. Equivalent lysis of both HLA-
A*0201- and B8-restricted targets is seen when bothzation assay using an HLA-A*0201-restricted, influenza
A M1-peptide-specific CTL clone which detects M1 pep- peptides were used at an equimolar pre-dialysis con-
centration of 150 nM (Figure 2A). At increasing HWD-tide-pulsed target cells to a concentration below 5 nM
(Figure 1B). Predialysis the NRL-M1 17-mer peptide- M1 peptide concentrations a concomitant rise in the
HLA-A*0201-restricted CTL response together with asensitized target cells for killing by the CTL clone only
Efficient Generation of Human CTL by HSP70
97
Figure 1. Mycobacterial HSP70-Peptide Com-
plexes Efficiently Prime Human DC for Induc-
tion of CD8 CTL Responses
(A) CTL induction by HSP70-peptide-pulsed
DC. Monocyte-derived human DC are pulsed
on day 7 with dialyzed HSP70-peptide com-
plexes (HSP70 concentration  220 nM) and
washed to remove unbound HSP70. Fresh
autologous CD8 T cells are coincubated with
primed DC for a further 7 days and assayed
by 51Cr release assay on peptide-pulsed B
cells or by tetramer staining.
(B) Fusion peptides require processing for
presentation on MHC class I molecules. Sen-
sitization of peptide-pulsed targets for killing
by an HLA-A*0201/M1-specific CTL clone was
compared for the minimal M1 peptide (open
circles), the NRL-M1 fusion peptide (closed
circles), and the NRL-M1 peptide postdialysis
(open triangles).
(C) Mycobacterial HSP70-peptide-pulsed DC
generate efficient peptide-specific CTL re-
sponses. HLA-A*0201-M1 tetramers were
used to compare generation of CTL from DC
pulsed with (i) HSP-70/NRL-M1 and (ii) HSP-
70-M1 peptide complexes. CD8 T cells alone
plus (iii) HSP70-NRL-M1 and (iv) HSP-70-M1
peptide complexes in the absence of DC. DC
pulsed with (v) NRL-M1 peptide alone, (vi) M1
peptide alone, (vii) LPS (100 ng) plus NRL-
M1, and (viii) LPS plus M1 peptide.
(D) A low number of HSP70-pulsed DC are
able to generate peptide-specific CTL re-
sponses. HSP70-peptide-pulsed DC were in-
cubated with CD8 T cells at a decreasing
DC:CD8 ratio from 1:25 to 1:25,000.
(E) HSP70-induced CTL responses are not
restricted to influenza A antigens. DC were
primed with either the standard HSP70/NRL-
M1 or HSP70 complexed with an HCMV
pp65-derived, HLA-A*0201-restricted pep-
tide and tested for peptide-specific killing on
day 7.
decrease in the HWD-NP-specific CTL response is seen and derived the equilibrium binding constant (KD) for the
HSP70-peptide interaction. This method has been used(Figure 2A), demonstrating that peptide competition for
binding HSP70 determines the specificity of the re- to investigate E. coli HSP70 (DnaK) peptide interactions
(Liu et al., 2003). Due to insolubility problems of thesulting CTL response. Furthermore, competition by
“empty” HSP70 to prevent peptide bound HSP70 from fluorescein-labeled NRL-M1 (f-NRL-M1) peptide, re-
sulting in poorly reproducible binding data, we synthe-priming DC to generate peptide-specific CTL (Figure 4D)
strongly suggests saturation of a mycobacterial HSP70 sized a fluorescent peptide (f-NRLLLTG) composed of
the HSP70 binding motif (Zhu et al., 1996). The KD forreceptor-mediated uptake system. A requirement for the
N-terminal HSP binding motif was more clearly seen f-NRLLLTG binding wild-type mycobacterial HSP70 was
calculated as 12 M (Figure 2D), comparable to a KD ofwith the HLA-B8-than HLA*A0201-restricted peptides
(Figure 2B). At least 5-fold more NP peptide is required 11M for the same peptide binding to DnaK (Burkholder
et al., 1996). The f-NRLLLTG peptide showed similarto elicit a similar response as the HWD-NP peptide,
despite the processing requirement of the longer pep- binding affinity for HSP70 as f-NRL-M1 (KD  14 M)
(Figure 3D) and was used in subsequent experiments.tide (Figure 2B).
Specific HSP70 binding was verified by showing at least
a 20-fold reduction in affinity when ATP was includedQuantitation of Peptide Bound to Mycobacterial
in the reaction buffer (data not shown), consistent withHSP70 Required for CTL Generation
previous studies (Mayer et al., 2000). We used these KDAn iodinated derivative of the HWD-NP fusion peptide
values to calculate that 120 pM HSP70 bound peptidedemonstrated direct binding of peptide to mycobacte-
is sufficient to prime DC to generate peptide-specificrial HSP70 (Figure 2C). However, it was critical to know
CTL (Figure 2E), while a 2000-fold higher concentrationhow much peptide, postdialysis remained bound to the
of free peptide (250 nM) was unable to generate a similarHSP70 and was therefore delivered to DC to generate
response. In a series of unrelated subjects we foundpeptide-specific CTL. We used fluorescence anisotropy
to measure peptide binding to mycobacterial HSP70 between 120–340 pM HSP70 bound peptide was suffi-
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Figure 2. Peptide Binding to Mycobacterial
HSP70 Is Specific, Is Saturable, and at Pico-
molar Concentrations Is Sufficient to Prime
DC to Generate Peptide-Specific CTL
(A) Competition for peptide binding to HSP70
between HLA-B8- and HLA-A*0201-restricted
fusion peptides. HSP70 was incubated with
a peptide mixture containing the HLA-B8-
restricted fusion peptide (HWD-NP) (at a fixed
concentration of 150 nM) and increasing con-
centrations of the HLA-A*0201-restricted
HWD-M1 peptide. After overnight dialysis to
remove unbound peptide, DC were pulsed
with the HSP70-peptide complex, and tested
for their ability to generate HLA-A*0201-
(open circles) and B8-restricted (closed cir-
cles), peptide-specific CTL.
(B) The fusion peptide NRL-NP bound to
HSP70 primes DC more efficiently than the
HSP70/NP peptide alone. DC were primed
with either HSP70/NRL-NP or HSP70/NP and
tested for peptide-specific killing on day 7.
(C) Direct binding of HWD-B8 peptide to
HSP70. 125I-HWD-NP peptide was bound to
HSP70, washed, boiled in SDS sample buffer,
and resolved by SDS-PAGE prior to autoradi-
ography.
(D) Binding affinity of HSP70 for fNRLLLTG
(fNR) as determined by fluorescence anisot-
ropy. One hundred nanomolar fNR was incu-
bated with HSP70 as described in the Experi-
mental Procedures. The data were fitted
using a 1:1 binding model to derive the KD.
(E) DC pulsed with picomolar concentrations
of mycobacterial HSP70 bound peptide are
sufficient to generate peptide-specific CTL.
DC were pulsed with either (1) the HSP70-
peptide complex from which unbound pep-
tide was removed by overnight dialysis (cir-
cles) or (2) free peptide with no dialysis
(squares). The initial (predialysis) peptide
concentration is shown on the x axis. The
derived postdialysis HSP70 bound peptide
concentrations, based on the KD of 14 M,
are shown in parentheses for each concen-
tration.
cient to generate M1-peptide-specific CTL. Since the plete peptide binding region but lacks the nucleotide
binding domain (Figure 3A) and stimulates chemokinemycobacterial HSP70 was used at a concentration of
and cytokine release (Wang et al., 2002). The smallest220 nM, this suggests that only 1/750–1/1500 HSP70
HSP70, denoted HSP70(359–494), represents the mini-molecules needs to have bound peptide to generate a
mal 136 amino acid peptide binding region and consistsCTL response.
of the -pleated sheet subdomain only (Figure 3A). Both
these proteins were expressed and purified as histidine-
The Minimal 136 Amino Acid Peptide Binding Domain tagged subunits (Figure 3B). Their binding affinities for
of Mycobacterial HSP70 Is Sufficient to Induce peptide fNRLLLTG were ascertained by fluorescence
a Peptide-Specific CTL Response anisotropy; the KD of HSP70(359–610) was 12M (Figure
The HSP70 C-terminal peptide binding domain (amino 3C), and that of HSP70(359–494) was 19 M (data not
acids 359–610) can be further subdivided into a -pleated shown). The KD of antigenic peptides fNRL-M1 and
sheet (amino acids 368–476) which binds peptide di- fNRL-NP was determined as 14 and 3 M, respectively
rectly and an -helical lid domain (amino acids 512–587) (Figures 3D and 3E). Functional comparison with wild-
which stabilizes the bound substrate through a pro- type mycobacterial HSP70 showed the substrate bind-
posed nucleotide-dependent conformational change ing domain HSP70(359–610) to be as good as full-length
(Zhu et al., 1996). mycobacterial HSP70 at generating CTL responses. The
To determine the minimal functional HSP70 domain minimal HSP70(359–494) construct was also efficient at
able to induce peptide-specific CTL, we made recombi- generating CTL, with the 1.5-fold decrease in peptide
nant HSP70 truncation proteins (Figure 3A). The HSP70 binding affinity accounting for the small reduction in
activity as compared with wild-type HSP70 (Figure 3F).truncation, denoted HSP70(359–610), contains the com-
Efficient Generation of Human CTL by HSP70
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Figure 3. The Substrate Binding Domain of
Mycobacterial HSP70 Is Sufficient for the
Generation of a Peptide-Specific CTL Re-
sponse
(A) Schematic representation of the HSP70
truncations. Wild-type HSP70 (1–625) con-
tains the nucleotide and peptide binding do-
main. In the truncated HSP70(359–610) the
nucleotide binding domain has been re-
moved. The minimal HSP70(359–494) trunca-
tion contains the minimal peptide binding do-
main alone.
(B) SDS-PAGE of the HSP70 truncations.
Lanes 1, 2, and 4 show the HSP70 fragments
described in (A), lane 3 shows the mutant
V410F(359-610) construct.
(C–E) Binding affinity of truncated HSP70(359–
610) for (C) fNRLLLTG, (D) fNRL-M1, and (E)
fNRL-NP peptide.
(F) Truncated HSP70-peptide complexes are
as efficient as wild-type HSP70 at inducing
CTL. NRL-M1 peptide was complexed to wild-
type (open circles), truncated HSP70(359–610)
(closed circles), and minimal HSP70(359–494)
(closed squares) and tested for the ability to
prime DC for CTL induction.
HSP70-Peptide Binding Mutants Induce the Release peptide binding affinity with the wild-type truncated
HSP70(359–610). The KD of the mutants (Figure 4B) wasof Chemokines and Cytokines but Fail
to Generate Antigen-Specific CTL 2 (V410L, KD  27 M) and at least 5.5 (V410F, KD 
65 M) lower than wild-type truncated HSP70(359–610)An important feature of HSP70 is its ability both to deliver
specific peptide and to stimulate chemokine and cyto- (KD 12M). The V410F KD is certainly an underestimate
due to our inability to saturate the low-affinity interac-kine release. To determine whether these two functions
of HSP70 are separable or whether it is critical for pep- tion. The functional consequence of this decreased pep-
tide binding activity was tested in our CTL assay (Figuretide binding and the HSP70 immunostimulatory proper-
ties to be encoded within the same molecule, we made 4C). DC pulsed with the HSP70(V410F) mutant were un-
able to generate peptide-specific CTL, while CTL gener-HSP70 peptide binding mutants. The design of the mu-
tants was based on studies on DnaK in which mutations ation was significantly impaired with the conservative
HSP70(V410L) mutant. However, both the V410L andin the hydrophobic peptide binding pocket make a major
contribution to substrate binding affinity (Mayer et al., V410F mutants were as effective as their equivalent wild-
type HSP70 at inducing the release of chemokines and2000). In DnaK, substitution of the highly conserved va-
line residue (position 436) by a phenylalanine causes cytokines from DC (Table 1). The HSP70(V410F) peptide
binding mutant has therefore allowed us to separate thea marked (at least 17-fold) reduction in DnaK peptide
binding affinity. We reasoned that mutation of the corre- two critical functions of HSP70, peptide delivery from
immunostimulation, as measured by chemokine and cy-sponding valine residue (V410) in mycobacterial HSP70
should interfere with peptide binding and delivery of tokine release. Furthermore, under conditions where cy-
tokine and chemokine release are identical, a decreasedantigenic peptide to DC. Therefore, two mutants at posi-
tion 410 of the truncated HSP70(359–610) protein were peptide binding affinity for HSP70 leads to a diminished
CTL response. The ability of all the empty mycobacterialmade: a conservative mutant in which the valine was
substituted by leucine (V410L), and the more radical HSP70 truncation proteins, as well as the V410F peptide
binding mutant (Figure 4D), to compete with peptide-valine to phenylalanine (V410F) mutation (Figure 4A).
Following expression and purification of these mutant loaded wild-type HSP70 to prevent DC priming and gen-
eration of peptide-specific CTL suggests that the trun-truncated HSP70(359–610) proteins, we compared their
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Figure 4. HSP70 Peptide Binding Mutants Separate Peptide Delivery from Chemokine and Cytokine Secretion
(A) Schematic representation of HSP70 peptide binding mutants showing the wild-type peptide binding domain (upper panel), the conservative
(V410L) substitution (middle panel), and the (V410F) substitution (lower panel) filling the peptide binding site and preventing peptide binding.
(B) The peptide binding affinity of HSP70 mutants is decreased as compared with wild-type HSP70. The KD of fNR peptide to HSP70(V410L)
and HSP70(V410F) mutants was determined by fluorescence anisotropy.
(C) HSP70 peptide binding mutants have an impaired (V410L) and abrogated (V410F) ability to generate CTL. NRL-M1 (250 nM) was complexed
to wild-type HSP70, wild-type truncated HSP70(359–610), and HSP70 truncation mutants (V410L) and (V410F) prior to dialysis and pulsing of DC.
(D) HSP70(V410F) competes with peptide-loaded HSP70 to prevent CTL generation. Peptide-loaded HSP70 (predialysis peptide concentration
150 nM) was incubated with DC in the presence of increasing concentrations of HSP70(V410F) for 2 hr, washed to remove unbound HSP70,
and tested for their ability to generate peptide-specific CTL.
(E and F) Direct binding of peptide by HSP70 is required for efficient CTL generation by HSP70-pulsed DC. (E) NRL-M1 peptide or (F) NRL-
NP peptide was incubated with (1) dialyzed, wild-type, truncated HSP70(359–610) (closed circles), (2) dialyzed (open squares) or (3) nondialyzed
(open circles) mutant HSP70(V410F), or (4) no HSP70 (closed squares) prior to pulsing of DC and generation of CTL. The initial (predialysis)
peptide concentration is shown on the x axis. The derived postdialysis HSP70 bound peptide concentrations, based on the KD of NRL-M1
(14 M) and NRL-NP (3 M), are shown in parentheses.
(G) Augmentation of the peptide-specific response by mycobacterial HSP70 is a trans effect. DC from two donors were incubated with low
dose (suboptimal concentration of 27.5 nM), wild-type truncated HSP70(359–610) complexed to NRL-M1 peptide (230 nM predialysis, 0.45
nM bound peptide postdialysis) in the presence or absence of the mutant HSP70(V410F) (200 nM).
cated proteins also encompass the receptor binding free peptide, the immunostimulatory properties of
HSP70 are sufficient to generate CTL, or whether theredomain.
The HSP70(V410F) mutant allowed us to address the is an absolute requirement for peptide to be HSP bound.
The V410F mutant does not bind peptide but retainsimportant issue of whether, in the presence of excess
Efficient Generation of Human CTL by HSP70
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Table 1. Mycobacterial HSP70 Induction of Chemokine and Cytokine Release from DC
IL-12 p70 RANTES IL-1 TNF- IL-6
(pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml)
Wild-type HSP70-peptide 125 550 220 540 266.6
 Proteinase K 20 20 20 20 20
 95C for 20 20 20 20 20 20
Truncated HSP70(359–610)/peptide 2646 1895 608 4141 2206
 Proteinase K 20 20 20 20 20
Truncated HSP70(V410F)/peptide 3197 1951 730 4655 1860
 Proteinase K 20 20 20 20 20
Truncated HSP70(V410L)/peptide 3054 2011 689 4491 2053
 Proteinase K 20 20 20 20 20
LPS (100 ng/ml)  peptide 5012 3555 1660 8549 2551
 Proteinase K 4500 3200 1250 7020 1980
 95C for 20 4780 3980 980 7210 1900
Peptide alone 20 233 20 20 120
Supernatants were taken from DC cultures stimulated for 72 hr in the presence of CD8 T cells. Data are expressed as the mean of dupli-
cate samples.
immunostimulatory properties. We therefore compared release of chemokines and cytokines. We initially re-
duced the LPS contamination in our mycobacterialCTL generation in DC pulsed with either the control,
HSP70 stocks by passing the proteins twice throughpeptide-loaded, dialyzed wild-type HSP70(359–610) or
columns loaded with polymixin B. The resulting proteinsthe peptide-loaded, nondialyzed HSP70(V410F) mutant
were tested by limulus amebocyte lysate (LAL) assay(Figures 4E and 4F). Even at a free NRL-M1 peptide
and only used if endotoxin contamination was less thanconcentration of 2000 nM, DC pulsed with the nondia-
5 EU/mg of HSP70. To ensure that LPS contaminationlyzed mutant HSP70(V410F) protein generated only
of our HSP70 was not responsible for the release ofpoor, low-level killing (11%), which was comparable to
chemokines and cytokines, the mycobacterial HSP70-the CTL lysis obtained with the control dialyzed wild-
peptide complexes were either boiled at 95C for 20 mintype HSP70(359–610) with bound peptide at 0.21 nM
or treated with proteinase K. Both of these treatments(10,000-fold higher) (Figure 4E). Indeed the mutant
abrogated HSP70-, but not LPS-, induced release ofHSP70(V410F) protein was only marginally superior to
chemokines and cytokines (Table 1), and prevented thefree peptide alone. Thus, even in the presence of excess
induction of peptide-specific CTL responses by HSP70-free peptide the adjuvant properties of mycobacterial
pulsed DC (Figure 5A). Furthermore, the addition of solu-HSP70 are insufficient to promote the efficient genera-
ble CD14 enhanced LPS-induced release of chemokinestion of CTL as compared with HSP70 bound peptide.
and cytokines (Table 2) but had no effect on mycobacte-The above experiments demonstrate a clear require-
rial HSP70-induced release, providing further evidencement for peptide to be bound to mycobacterial HSP70
against endotoxin contamination contributing to DC ac-for efficient presentation. We designed an experiment to
tivation (Bausinger et al., 2002).determine whether the peptide and immunostimulatory
To further differentiate the intracellular signaling path-properties of HSP70 need to be delivered by the same
way utilized by mycobacterial HSP70 from the TLR path-HSP70 (cis effect) or can be delivered on separate
way implicated in LPS signaling, we investigated theHSP70 molecules (trans effect). DC were pulsed with
effect of mycobacterial HSP70 on intracellular calciumdialyzed wild-type HSP70/NRL-M1 peptide complexes
fluxes. Human HSP70 triggers a calcium-dependent sig-under conditions which ensured the bound NRL-M1
naling pathway in monocytes (Asea et al., 2000), andpeptide was not limiting (0.45 nM), but the HSP70 con-
stimulation with calcium ionophores induces DC matu-centration was suboptimal (27.5 nM) and therefore gen-
ration (Czerniecki et al., 1997). When full-length myco-erated a poor CTL response (Figure 4G). Experiments
bacterial HSP70, truncated HSP70(359–610), or mutantfrom two subjects show that when sufficient peptide is
HSP70(V410F) was added to human DC labeled with aHSP70 loaded, but the HSP70 concentration is itself
calcium-sensitive dye, there was a clear induction oflimiting, addition of excess “peptide-free” HSP70(V410F)
intracellular calcium responses which was quantifiedis able to enhance a poor CTL response (Figure 4G).
by cuvette fluorimetry (Figure 5B). In contrast, and as
predicted from the absence of TLR4-mediated calcium
The Induction of CTL by Mycobacterial HSP70 signaling, LPS was unable to induce any significant in-
Is Calcium Dependent tracellular calcium response (Figure 5B). This mycobac-
Activation of cells of the innate immune system by HSPs, terial HSP70-mediated induction of intracellular calcium
including mycobacterial HSP70 (Wang et al., 2002), has could be followed at the single-cell level by confocal
been reported. Many of the HSPs employed in these microscopy (Figure 5C). Following the addition of 200
studies were bacterial recombinant proteins, and some nM mycobacterial HSP70, a marked increase in fluores-
of the receptors and signaling pathways identified are cence levels of the calcium-sensitive Fluo-3 dye was
the same as those used by bacterial LPS. It was there- observed over a 5 min period, an effect not seen with
fore critical to show that LPS contamination of our myco- LPS (data not shown). The physiological nature of the
mycobacterial HSP70 stimulus was demonstrated bybacterial HSP70 proteins was not responsible for the
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Figure 5. Mycobacterial HSP70 Triggers a Functional, Calcium-Dependent Signaling Cascade Not Seen with Lipopolysaccharide
(A) Mycobacterial HSP70 complexes treated with proteinase K or boiled for 20 min are unable to prime DC for CTL induction.
(B–D) Mycobacterial HSP70 induces intracellular calcium which can be visualized at the single-cell level. (B) Cuvette fluorometric measurements
of intracellular calcium following addition of wild-type mycobacterial HSP70 (black), HSP70(359–610) (red), mutant HSP70(V410F) (green) (all
at 200 nM), or LPS (1 g/ml) (blue) to Fura2-loaded human DC. (C) Superimposed DIC and confocal fluorescence images of Fluo3-loaded DC
shows induction of intracellular calcium signaling following addition of mycobacterial HSP70 (200 nM) (at time point 10 s). Size bar  30 m.
(D) To analyze the intracellular calcium changes in (C), fluorescence recordings taken at 3 s intervals were corrected for dye photobleach and
expressed as % of maximum fluorescence (Fmax) following addition of 5 M ionomycin. Changes in intracellular calcium as assessed by fluo-3
fluorescence from three representative cells stimulated with either mycobacterial HSP70 (upper panel) or LPS (1 g/ml) (lower panel) are shown.
(E) The intracellular calcium chelator BAPTA prevents the HSP70-dependent generation of peptide-specific CTL. DC were incubated for 30
min in the presence or absence of BAPTA-AM, washed, pulsed with the indicated complexes, and tested for their ability to generate peptide-
specific CTL.
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Table 2. Soluble CD14 Increases LPS-, but Not HSP70-, Induced Chemokine and Cytokine Release from DC
IL-12 p70 RANTES IL-1 TNF- IL-6
(pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml)
Wild-type HSP70-peptide 102.5 840 225 515 2105
Wild-type HSP70-peptide  sCD14 105.5 570 211 540 2200
Truncated HSP70(359–610)/peptide 998 2520 980 2460 6640
Truncated HSP70(359–610)/pep  sCD14 1028 2321 780 2350 4620
LPS (100 ng/ml)  peptide 1089 4180 1024 3610 1320
LPS (100 ng/ml)  peptide  sCD14 8633 8940 2010 8276 4400
Supernatants were collected from DC cultures stimulated for 72 hr in the presence of CD8 T cells. Data are expressed as the mean of
duplicate samples.
assessing the calcium response within single represen- to achieve an HLA-A*0201/M1 tetramer frequency of
tative cells over the duration of the assay (Figure 5D). between 15% and 45% over a 7 day culture period. This
Mycobacterial HSP70 triggered regular oscillations in rapid lymphocyte doubling time suggests a mechanism
calcium signaling (upper panel), while LPS was unable which allows both the efficient delivery of antigen and
to induce a significant calcium response in individual stimulation of DC to secrete cytokines and chemokines.
cells (lower panel). To demonstrate the functional rele- Indeed, this system was more efficient at generating
vance of calcium signaling in the mycobacterial HSP70- CTL than using high concentrations of free peptide with
mediated generation of CTL, we used the intracellular any other DC activator, including LPS, poly I:C, or influ-
calcium chelator BAPTA, loaded as the AM ester at a enza A virus.
dose of 20 M which attenuates any HSP70 triggered The efficiency of the mycobacterial HSP70 system
rise in intracellular calcium (data not shown). In three reflects the fact that delivered peptide is HSP70 bound.
subjects, BAPTA-AM treatment of HSP70-peptide- The concentration of peptide bound HSP70 required
loaded DC for 30 min diminished the ability of these to generate a CTL response has not been previously
cells to generate a peptide-specific CD8 T cell response measured. Deriving the KD values allowed us to deter-
by 60% (Figure 5E), without affecting DC viability. Thus, mine that 120 pM HSP bound peptide is sufficient to
mycobacterial HSP70 induces a calcium signaling cas- prime DC to generate a CTL response. That such a low
cade which appears to be critical for its functional ef- concentration of bound peptide can generate antigen-
fects. specific CTL suggests that HSP70-mediated peptide
delivery to the class I pathway may indeed be physio-
logical. Peptide binding in vivo will be facilitated byDiscussion
DnaJ- and GrpE-like chaperones in prokaryotes (Mayer
et al., 2000), and similar chaperones exist in mammalianWe have examined the role played by mycobacterial
cells. From the therapeutic viewpoint, the relatively lowHSP70 in generating CTL responses in human DC. My-
binding affinity of NRLLL-coupled peptides for myco-cobacterial HSP70-peptide-pulsed DC generate human
bacterial HSP70 suggests that these binding motifsCTL with remarkable efficiency when compared to other
need to be optimized, at least for mycobacterial HSP70.DC activators. A series of HSP70 truncations have identi-
The specificity of the HSP70-peptide interaction wasfied the minimal 136 amino acid substrate binding sub-
further emphasized by the generation of single aminounit to be efficient at generating peptide-specific CTL,
acid HSP70 peptide binding mutants, in which the hy-and 120 pM HSP70 bound peptide is sufficient to gener-
drophobic peptide binding site is filled with bulky sideate a CTL response. The HSP70 mutant proteins with a
chains to prevent peptide binding (Mayer et al., 2000).decreased affinity for peptide have allowed us to sepa-
These mutant proteins were made in an attempt to sepa-rate the two major properties of HSP70, peptide binding
rate two of the main properties of HSP70, peptide bind-from chemokine and cytokine release. We find an abso-
ing from cytokine and chemokine release. Both theselute requirement for peptide to be HSP bound, as even
mutants were as efficient as wild-type truncated HSP70in the presence of excess peptide, mutant HSPs with a
at inducing cytokine and chemokine release from DC,low peptide binding affinity are unable to prime DC for
but showed either a partial (V410L) or complete (V410F)the efficient generation of CTL. Furthermore, we show
inability to generate CTL. These mutants allowed usthat in human DC mycobacterial HSP70 induces a cal-
to separate HSP-mediated peptide delivery from HSP-cium-dependent signaling pathway required for efficient
mediated cytokine and chemokine release. In the pres-CTL generation.
ence of the HSP70(V410F) mutant, even free peptidePrevious studies in the human system have focused
concentrations up to 2000 nM were unable to prime DCon the “adjuvant function” of HSP70. We now show that
to generate an effective peptide-specific CTL response.mycobacterial HSP70-peptide stimulation of DC is an
These results emphasize the specificity of peptide bind-efficient method for generating human CTL in all healthy
ing and indicate that, despite efficient DC activation,HLA-A*0201 subjects tested. Our published CTL precur-
below a threshold of 100–200 pM HSP bound peptidesor frequencies to the HLA-A*0201-restricted influenza
it is not possible to generate CTL. Delivery of HSP70M1 epitope range from 1/54,000 to 1/250,000 from
bound peptide to a specific intracellular compartmentfreshly isolated PBMC (Lehner et al., 1995). We therefore
estimate a T cell doubling time of between 11–13 hr is presumably required for loading of class I molecules
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and agrees with studies showing that binding and up- or indirectly, contribute to the immunostimulatory prop-
erties of the HSP. These concerns are particularly impor-take of HSP70 is receptor mediated.
Does efficient CTL generation require both the peptide tant as HSPs are abundant and bind both proteinaceous
and nonproteinaceous material, and a recent report sug-and the adjuvant properties of HSP70 to be delivered
by the same protein (cis), or can they be separated and gested that thorough removal of contaminating LPS
(10 EU/mg) does not prevent peptide delivery, butstill deliver the same response (trans)? This issue is of
importance in situations where the HSP70 bound pep- does abrogate human HSP70 activation of human DC
(Bausinger et al., 2002). Furthermore, the description oftide complex is limiting—can the immunostimulatory
properties of other HSP70s boost the response to an HSP70 signaling via TLRs does not help discriminate
LPS- from non-LPS-mediated pathways (Vabulas et al.,HSP70-peptide complex present at limiting concentra-
tions? We addressed this issue by stimulating DC with 2002). To address these important concerns we have
initially “cleaned” all our HSP preparations immediatelypeptide bound to a fixed suboptimal concentration of
wild-type HSP70. The presence of excess mutant empty prior to use by running them twice through a polymyxin
column and assaying LPS concentrations via the LALHSP70(V410F) was indeed able to boost the response
above a limiting threshold. assay. All HSP70 preparations used in this study have
LPS concentrations less than 5 EU/mg and while addi-HSP70s oligomerize through their substrate binding
domain, a process promoted by high concentrations of tion of soluble CD14 enhanced chemokine/cytokine re-
lease by LPS, it had no effect on HSP70-mediated re-ATP and peptide (Azem et al., 1997). The HSP70(V410F)
mutant allows us to ask whether HSP70 oligomerization lease. To preclude an effect of LPS we have shown that
both boiling the mycobacterial HSP70 at 95C for 20 minis required for signaling. By crosslinking analysis and
or, alternatively, treatment of the HSP70 with proteinasegel filtration studies we estimate that about 20% of our
K abrogates both the generation of CTL and the releasewild-type HSP70 exists in the monomeric form, while
of chemokines and cytokines. Neither of these two treat-the remainder of the protein exists as oligomers, pre-
ments affects the ability of LPS, at high (500 ng/ml) ordominantly dimers and trimers. The HSP70(V410F) mu-
low concentrations (10 ng/ml) to activate DC or inducetant exists as only a single monomeric species but
chemokine and cytokine release. An additional concernremains immunostimulatory, suggesting that oligomeri-
is the observation that LPS may bind HSP70 via thezation is not required for this signaling function of HSP70
substrate binding domain and would not be detectedbut may still be required for efficient peptide delivery.
in our LAL assay. This remains a formal possibility,The delivery of antigenic peptides by carrier proteins
though the peptide binding mutant (V410F) would be nounable to stimulate chemokine and cytokine release,
more likely to accommodate LPS than a peptide residuesuch as bovine serum albumin, is insufficient to generate
and retains the immunostimulatory properties.CTL responses (Menoret et al., 1999), emphasizing the
In a further attempt to separate LPS- from non-LPS-importance of activating cells of the innate immune sys-
mediated signaling pathways, we investigated HSP70-tem by HSPs. It is known that the peptide binding do-
induced calcium signaling in primary human DC. Myco-main of mycobacterial HSP70 (359–610) rather than the
bacterial HSP70 induces triggering of calcium signalingATPase subunit (1–358) mediates the chemokine and
in DC, which could be visualized as calcium oscillationscytokine release seen following stimulation with myco-
at the single-cell level. This signaling activity is neverbacterial HSP70 (Wang et al., 2002). A series of HSP70
seen with LPS, nor is calcium signaling a feature oftruncations were therefore designed to determine whether
signaling via members of the TLR family, includingthe peptide binding and immunostimulatory properties
TLR-4, the LPS receptor. Furthermore, inhibition of theof mycobacterial HSP70 reside within the same HSP70
calcium signaling with the intracellular BAPTA-AM cal-subunit and the minimal HSP70 subunit required to
cium chelator prevented the ability of mycobacterialprime DC for CTL generation. The wild-type and trun-
HSP70 to efficiently generate peptide-specific CTL.cated HSP70(359–610) have similar peptide binding af-
These results suggest both an HSP70-induced, calcium-finities and were equally effective at stimulating DC to
dependent signaling pathway and provide evidence thatgenerate CTL. The minimal HSP70(359–494) had a
mycobacterial HSP70 stimulates DC via a TLR-indepen-slightly reduced affinity for peptide (1.6-fold lower) and
dent mechanism, and is therefore unlikely to representwas therefore marginally less efficient at stimulating DC
contaminating LPS.to generate CTL. These results are in contrast with stud-
We have demonstrated the efficiency with whichies showing that Mycobacterium leprae HSP70 requires
HSP70 bound peptide can generate a CTL response.the ATP binding unit to retain functional activity in mice
The low concentrations of HSP70 bound peptide sug-(Huang et al., 2000). Apart from the species difference,
gests a physiological role for HSP70 bound peptide inthe major distinction between these studies is that we
accessing the class I antigen presentation pathway andused peptides noncovalently bound to HSP70 while in
will allow further optimization of HSP70 binding pep-the previous study the antigenic peptide was fused to
tides. These results provide an important rationale forthe C terminus of the HSP70. The processing require-
investigating the utility of HSPs for clinical use in vivoments for the HSP70 fusion proteins are therefore likely
and a potentially useful therapeutic method for generat-to be different from noncovalently bound peptides.
ing human CTL in vitro.A major concern in studying the immunological prop-
erties of HSPs is the potential for contamination with
Experimental ProceduresLPS or other excipients which may be present in both
recombinant and tissue-derived HSP preparations, and Peptides and Reagents
be functionally active at extremely low concentrations. The peptides NRL-M1 (NRLLLTGSGILGFVFTL), M1 (GILGFVFTL),
HWD-M1 (HWDFAWPWGSGILGFVFTL), NP (ELRSRYWAIRTR),If present, these contaminating products could, directly
Efficient Generation of Human CTL by HSP70
105
NRLLLTGSGELRSRYWAIRTR (NRL-NP), and HWD-NP (HWDFAWP Cytokine and Chemokine Measurements
Supernatants were collected from cultures of stimulated DC andWGSGELRSRYWAIRTR) were purchased (University of Bristol). The
N-terminal fluorescein-labeled peptides fNRLLLTG (fNR) and T cells 72 hr poststimulation. RANTES was measured by ELISA
(Wang et al., 2001). IL-12p70, IL-1, TNF-, and IL-6 were measuredfNRLLLTGSGILGFVFTL were kindly made by David Owen and Assaf
Friedler, respectively (MRC LMB, Cambridge, UK). LPS (Sigma) was by cytometric bead array analysis (BD biosciences).
from E. coli (J5 strain). Proteinase-K Sepharose (Sigma) was incu-
bated with HSP70-peptide or LPS for 3 hr at 37C. The supernatant Measurement of Cytosolic Calcium
was analyzed by SDS-PAGE, and silver staining confirmed complete Cells were loaded with fluorescent calcium indicator by incubation
HSP70 degradation. The soluble CD14 was obtained from Biometec. with either 1 M Fura2-AM (for cuvette fluorimetry experiments) or
5 M Fluo3-AM (for single-cell confocal imaging) and an equal vol-
ume of 20% Pluronic F127 (Molecular Probes) for 45 min at roomDendritic Cell Purification and Culture
temperature in HEPES-buffered saline containing 2 mM CaCl2 andHuman PBMC were isolated from the peripheral blood of healthy
stored on ice. Fura-2-fluorescence measurements of cell popula-HLA-A*0201 and/or HLA-B8 volunteers using Ficoll-Hypaque den-
tions were assessed using a Cairn Spectrophotometer (Melendezsity gradients. Peripheral blood monocytes were enriched from the
et al., 1998). For single-cell calcium measurements, Fluo-3-loadedPBMC by negative selection utilizing a MACs-based monocyte puri-
cells were settled on poly-L-lysine-coated coverslips in a perfusionfication kit (Miltenyi). DC were generated by culturing the monocytes
chamber at 37C and imaged using a Zeiss inverted confocal micro-in 100 ng/ml GM-CSF and 1000 U/ml of IL-4 for 7 days in supple-
scope. Frames were acquired every 3 s (1024	 1024 pixels assignedmented DMEM and 10% heat-inactivated autologous serum. The
a 12 bit intensity value) with simultaneous DIC images to excludepurity of the DC populations was 
90% as determined by flow
artifactual changes in fluorescence caused by cell movement withincytometry staining with anti-human CD83 (HB15a), CD86 (BU63),
the focal plane. Results were adjusted for dye photobleach as-class I (w632), and class II (L243) (MacAry et al., 2001).
sessed in unstimulated cells and expressed as a fraction of maxi-
mum fluorescence (Fmax) obtained for each cell by addition of 5 M
Generation of CTL Responses Using Mycobacterial ionomycin at the end of each experiment.
HSP70-Peptide Complexes
Autologous CD8 T cells were purified to
99% by positive selection Fluorescence Anisotropy
(Miltenyi). Day 7 human DC were pulsed with 650l dialyzed HSP70- All anisotropy measurements were performed using a Perkin-Elmer
peptide complexes for 2 hr at room temperature, washed twice to LS-50b luminescence spectrofluorimeter. One hundred nanomolar
remove unbound HSP70-peptide complexes, and transferred to flat- fluorescent peptide was incubated with varying concentrations of
bottomed 96-well plates (Nunc) at 1 	 104/well in DMEM with 10% HSP70 for 5 hr at 30C in K2/Mg2 buffer (25mM K-HEPES [pH
autologous serum. Purified CD8 T cells were added (2.5 	 105/ 7.4], 100 mM KCl, 5 mM MgCl2) in the dark to allow equilibration.
well) and cocultured with the HSP70-pulsed DC for 7 days with IL-2 Measurements were taken using excitation at 490 nm and emission
(5 U/ml). at 520 nm, and with 2.5 nm excitation, 17 nm emission slit widths.
The data were fitted to 1:1 binding equilibrium model using Grafit
Preparation and Microdialysis of HSP70-Peptide Complexes (Erithacus software). For measurements using fluorescent NRL-M1,
Peptides were bound to HSP70 (10 g) for 40 min at 20C in PBS the binding reaction was performed in 4% DMSO, since the peptide
buffer containing 1 mM KCL, 2 mM MgCl2, 10 nM ATP in a total was insoluble in a purely aqueous buffer.
volume of 650 l. ADP (100 nM) was added for a further 40 min at
20C. Nucleotide was omitted from peptide binding with the trun- Space-Filling Model Construction
cated fragments. Unbound peptide was removed from the HSP- The primary sequence of mycobacterial HSP70 was entered into
peptide complexes by overnight microdialysis in 0.5 ml tubes with Swiss-Model (http://ca.expasy.org/). This was aligned with the se-
a 14 kDa membrane cutoff. Removal of free peptide from HSP- quences of HSP70s with derived crystal structures to generate a
peptide complexes was confirmed by pulsing 51Cr-labeled target model structure which was rendered into a space-filling diagram
cells with the dialysate and assaying the targets in a standard cyto- using PyMOL (http://pymol.sourceforge.net/).
toxicity assay using an HLA-A*0201-restricted, M1 peptide-specific
CTL clone, which detects free M1 peptide to a concentration of Acknowledgments
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